Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis

Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Different treatment trials have been published in acquired nystagmus in the last decade; gabapentin and memantine have been found to be efficient in treating pendular nystagmus in Multiple Sclerosis. The effects of treatments are measured on nystagmus velocity, amplitude, frequency and on visual acuity. None of the trials measured a functional visual score or oscillopsia score. The aim of our study is to evaluate the effect of gabapentin and memantine on the mean velocity, amplitude and frequency of pendular nystagmus, as well as on oscillopsia, visual acuity and vision-specific health-related quality of life score, in 10 patients with multiple sclerosis. The primary object is to find out the best variable to evaluate the efficiency of nystagmus treatment and the secondary, to compare the efficiency of both gabapentin and memantine in a common population of patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: No
View:

• All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria.

• All patients may present a chronic acquired pendular nystagmus due to MS, observed over a period of 6 months.

• All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee.

• Age: above 18

• Able to understand the instructions

• Having a health coverage

• Able to sit down for 1 hour

• Stable dosage of previous medications (beginning 3 weeks previously and terminating at the end of the trial duration), except for steroids, gabapentin or memantine.

Locations
Other Locations
France
Hôpital Neurologique Unité de Neuro-Ophtalmologie
Bron
Time Frame
Start Date: November 2012
Completion Date: July 2013
Participants
Target number of participants: 10
Treatments
Experimental: Memantine first
Experimental: Gabapentin first
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov

Similar Clinical Trials